Samsung Biologics Secures $1.3 Billion US Contract Manufacturing Deal

Strategic Insights -

Despite the ongoing uncertainty in the Trump administration's international trade policy, Samsung Biologics, a Korean biopharmaceutical company, has struck a billion-dollar contract manufacturing deal with a US-based pharmaceutical company. This deal, valued at 1.8 trillion Korean won (approximately $1.3 billion), will run through December 31, 2029, and marks the company's second-largest contract since its founding in 2011.

Key Takeaways:

  • Samsung Biologics has secured a contract manufacturing deal with a US-based pharmaceutical company, valued at 1.8 trillion Korean won (approximately $1.3 billion).
  • The deal will run through December 31, 2029, with a possible change in the contract timeline in the future.
  • This contract is the second-largest Samsung Biologics has inked since its founding in 2011.
  • Samsung Biologics has previously secured high-value production contracts, including a separate contracting deal with an undisclosed US drugmaker valued at 737 billion won (approximately $531 million) and a $1.2 billion manufacturing contract through 2037 with an unnamed Asia-based drugmaker.
  • The company's production footprint is still concentrated in South Korea, but it is considering a potential US manufacturing site.
  • Samsung Biologics has suggested that its expansive production capacity and steady record of success provide a competitive edge strong enough to offset tariff risks.

Statistics:

  • 1.8 trillion Korean won (approximately $1.3 billion): the value of the contract manufacturing deal between Samsung Biologics and the US-based pharmaceutical company.
  • December 31, 2029: the end date of the contract manufacturing deal.
  • 737 billion won (approximately $531 million): the value of a separate contracting deal between Samsung Biologics and an undisclosed US drugmaker.
  • November 2023: the time frame when Samsung Bio announced its plans for a potential US manufacturing site.
  • 1.29 trillion won (approximately $936 million): Samsung Biologics' revenue in the second quarter of 2025, an 11% increase from the previous year.

Sources:

  • Bloomberg: "Samsung Biologics Wins $1.3 Billion Contract Manufacturing Deal"
  • Korea JoongAng Daily: "Samsung Bio Inks 2nd-Largest Contract Since Founding"
  • Seeking Alpha: "Samsung Biologics SG Clean Energy ESG ETF"